JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Search

Smith & Nephew PLC ADR

Gesloten

34.23 0.38

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

33.95

Max

34.23

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

30.423

90.422

Dividendrendement

2.26

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+0.94% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.26%

2.13%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

15B

Vorige openingsprijs

33.85

Vorige sluitingsprijs

34.23

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Smith & Nephew PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 feb 2026, 23:52 UTC

Acquisities, Fusies, Overnames

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb 2026, 23:52 UTC

Acquisities, Fusies, Overnames

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb 2026, 23:38 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb 2026, 23:28 UTC

Marktinformatie

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb 2026, 23:23 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb 2026, 22:57 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb 2026, 22:08 UTC

Marktinformatie

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb 2026, 21:51 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 feb 2026, 21:49 UTC

Winsten

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb 2026, 21:39 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:36 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb 2026, 21:34 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:28 UTC

Acquisities, Fusies, Overnames

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb 2026, 21:23 UTC

Winsten

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb 2026, 21:19 UTC

Winsten

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb 2026, 21:17 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb 2026, 21:17 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:10 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:08 UTC

Winsten

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb 2026, 21:07 UTC

Winsten

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q EPS 24c >PLTR

2 feb 2026, 20:40 UTC

Marktinformatie

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC ADR Prognose

Koersdoel

By TipRanks

0.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 34.46 USD  0.94%

Hoogste 34.91 USD

Laagste 34 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Technische score

By Trading Central

26.64 / 28.37Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat